QTRX — Quanterix Corp
NASDAQ · Healthcare · Medical Devices
$2.52
+$0.02 (+0.60%)
Quanterix Corp (QTRX) is a medical devices company listed on NASDAQ. It is led by Masoud Toloue Ph.D., based in Building 1, Billerica, MA, United States, 01821, with about 471 employees. Quanterix Corporation, a life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications. It also provides SP-X instrument that is based on Simoa planar array technology for the measurement of multiplex chemiluminescent immunoassays. The company's products include assays include all components required to run enzyme-based immunoassay, such as beads, capture and detector reagents, and enzyme reagents and substrate; and replacement parts, reagents, and antibodies. In addition, the company offers contract research services, including sample testing, homebrew assay development, custom assay development, lucent diagnostic, and LDT testing services. The company primarily operates in the areas of neurology, oncology and immunology, and inflammation. It sells its products for the life science research sector primarily to laboratories associated with academic and governmental research institutions, as well as pharmaceutical, biotechnology, and contract research companies through a direct field sale, support organizations, and distributors or sales agents. The company was formerly known as Digital Genomics, Inc. and changed its name to Quanterix Corporation in August 2007. Quanterix Corporation was incorporated in 2007 and is headquartered in Billerica, Massachusetts.
Latest reported QTRX revenue for 2025-09-30 was $40.2M. Net income was -$84.0M. Revenue was up 64.4% from 2025-06-30 to 2025-09-30. QTRX currently screens at market cap $274.8M.
Use this QTRX page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the QTRX quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the QTRX SEC filings page. Lician reads the product cache first so this HTML stays unique to Quanterix Corp even when a live quote feed is slow.
About Quanterix Corp
Quanterix Corporation, a life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications. It also provides SP-X instrument that is based on Simoa planar array technology for the measurement of multiplex chemiluminescent immunoassays. The company's products include assays include all components required to run enzyme-based immunoassay, such as beads, capture and detector reagents, and enzyme reagents and substrate; and replacement parts, reagents, and antibodies. In addition, the company offers contract research services, including sample testing, homebrew assay development, custom assay development, lucent diagnostic, and LDT testing services. The company primarily operates in the areas of neurology, oncology and immunology, and inflammation. It sells its products for the life science research sector primarily to laboratories associated with academic and governmental research institutions, as well as pharmaceutical, biotechnology, and contract research companies through a direct field sale, support organizations, and distributors or sales agents. The company was formerly known as Digital Genomics, Inc. and changed its name to Quanterix Corporation in August 2007. Quanterix Corporation was incorporated in 2007 and is headquartered in Billerica, Massachusetts.
QTRX Key Statistics
Market Cap
$274.80M
Volume
503,125
Previous Close
$2.80
Day Range
$2.77 – $2.96
EPS
-$1.00
Revenue
$137.42M
Net Income
-$38.53M
Gross Profit
$0.00
Free Cash Flow
$0.00
Revenue Growth
+12.3%
Profit Margin
-28.0%
Employees
471
QTRX Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $137.42M | $122.37M | $105.52M | $110.56M |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$38.53M | -$28.35M | -$99.57M | -$57.69M |
| EPS (Diluted) | -$1.00 | -$0.75 | -$2.69 | -$1.60 |
Total Assets
$406.53M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$56.71M
Operating Cash Flow
-$35.16M
Free Cash Flow
$0.00
Quanterix Corp Company Information
- President, CEO & Director
- Masoud Toloue Ph.D.
- Headquarters
- Building 1, Billerica, MA, United States, 01821
- Website
- www.quanterix.com
- Phone
- 617 301 9400
- IPO / Founded
- 2017-12-07
- Sector
- Healthcare
- Industry
- Medical Devices